626 related articles for article (PubMed ID: 33753421)
21. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines.
Kopylov U; Levin A; Mendelson E; Dovrat S; Book M; Eliakim R; Ben-Horin S
Aliment Pharmacol Ther; 2012 Jul; 36(2):145-50. PubMed ID: 22612376
[TBL] [Abstract][Full Text] [Related]
22. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
[TBL] [Abstract][Full Text] [Related]
23. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
Wong SY; Wellens J; Helmus D; Marlow L; Brann S; Martinez Pazos V; Weinberg A; Moran HR; McGregor C; Vermeire S; Watanabe K; Kamikozuru K; Ahuja V; Vermani S; Lindsay JO; Kingston A; Dutta U; Kaur H; Silverberg MS; Milgrom R; Chien Ng S; Mak JWY; Cadwell K; Thompson C; Colombel JF; Satsangi J;
Inflamm Bowel Dis; 2023 Nov; 29(11):1693-1705. PubMed ID: 37354560
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
25. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
Dai C; Dong ZY; Wang YN; Huang YH; Jiang M
Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949
[TBL] [Abstract][Full Text] [Related]
26. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
27. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
[TBL] [Abstract][Full Text] [Related]
28. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
[TBL] [Abstract][Full Text] [Related]
29. Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Boland BS; Goodwin B; Zhang Z; Bloom N; Kato Y; Neill J; Le H; Tysl T; Collins AE; Dulai PS; Singh S; Nguyen NH; Grifoni A; Sette A; Weiskopf D; Chang JT; Dan JM
Clin Transl Gastroenterol; 2022 Apr; 13(4):e00484. PubMed ID: 35347100
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
31. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.
Ray K
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):286. PubMed ID: 33785883
[No Abstract] [Full Text] [Related]
32. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
[TBL] [Abstract][Full Text] [Related]
33. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
34. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM
Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269
[TBL] [Abstract][Full Text] [Related]
36. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
[TBL] [Abstract][Full Text] [Related]
37. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
[TBL] [Abstract][Full Text] [Related]
38. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.
Edelman-Klapper H; Zittan E; Bar-Gil Shitrit A; Rabinowitz KM; Goren I; Avni-Biron I; Ollech JE; Lichtenstein L; Banai-Eran H; Yanai H; Snir Y; Pauker MH; Friedenberg A; Levy-Barda A; Segal A; Broitman Y; Maoz E; Ovadia B; Golan MA; Shachar E; Ben-Horin S; Perets TT; Ben Zvi H; Eliakim R; Barkan R; Goren S; Navon M; Krugliak N; Werbner M; Alter J; Dessau M; Gal-Tanamy M; Freund NT; Cohen D; Dotan I;
Gastroenterology; 2022 Feb; 162(2):454-467. PubMed ID: 34717923
[TBL] [Abstract][Full Text] [Related]
39. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.
Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D
PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
